Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin plus Gemcitabine and Nab-Paclitaxel in Metastatic PDAC
NCT04523987Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2019
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciprofloxacin in pancreatic ductal adenocarcinoma (PDAC), sponsored by National University Hospital. Primary endpoint: Antitumor Effect - Solid Tumors at 4 years. Started Feb 2019; status: active, not recruiting.
02
Drugs
ciprofloxacin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04523987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523987.